Alina, was then working as a teacher at a secondary school in Kajang, Selangor. Initially, she thought her condition was due ...

Myasthenia gravis (MG) is a chronic autoimmune condition that affects signaling between the body’s nerves and muscles, leading to muscle weakness. Symptoms of MG can appear anywhere on the body ...

Richard J. Nowak, MD, MS, Yale School of Medicine, explains what some early myasthenia gravis symptoms are and their impact on research efforts.

Ultomiris (ravulizumab-cwvz) is a brand-name infusion prescribed for myasthenia gravis. This article covers topics such as side effects, dosage, and how Ultomiris works. Ultomiris is an ...

Dr Nicholas Silvestri reports that the 2025 AAN meeting highlighted significant advances in myasthenia gravis, including ...

SAN DIEGO -- Inebilizumab (Uplizna) improved function and reduced disease severity for up to 52 weeks in generalized myasthenia gravis (gMG) patients who were acetylcholine receptor (AChR ...

The myasthenia gravis treatment market is anticipated to grow at a CAGR of 7.14% from US$1.973 billion in 2025 to US$2.785 ...

People who suffer from the autoimmune disease myasthenia gravis experience muscle weakness that can affect any of the muscles we use to blink, smile or even move our body around. Researchers have ...

Research presented at the recent annual meeting of the Academy of Managed Care Pharmacy highlights outcomes among patients ...

Sanofi is still plugging away with its oral BTK inhibitor tolebrutinib in multiple sclerosis, but has decided to abandon efforts to develop the drug for neuromuscular disorder myasthenia gravis.

Watchers of the percolating myasthenia gravis space are waiting eagerly for data from Dianthus Therapeutics Inc.’s phase II Magic study testing DNTH-103, an active C1s inhibitor, compared to placebo ...

Autoimmune generalized myasthenia gravis is a disease that manifests with fluctuating muscle weakness. Inebilizumab is a monoclonal antibody that depletes CD19+ B cells, which are central to ...